Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

POINT BIOPHARMA GLOBAL INC.

(PNT)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
7.940 USD   -1.98%
02/02POINT Biopharma to Participate in Upcoming Investor Conferences
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialEnrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lantheus and Point Biopharma Announces Strategic Collaboration and Exclusive License Agreements for the Commercialization of Pnt2002 & Pnt2003

11/14/2022 | 07:00am EST

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. announced a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights to POINT's PNT2002 and PNT2003 product candidates. Upon consummation of the agreements, in exchange for the exclusive worldwide rights, Lantheus will pay a total of $260 million in upfront payments between the two agreements to POINT, with the potential for additional milestone payments of approximately $1.8 billion between the two products based on U.S. Food and Drug Administration (FDA) approval and net sales and commercial milestones. Additionally, Lantheus will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003.

The agreements expand Lantheus' radiopharmaceutical portfolio with two late-stage therapeutic candidates and, with PNT2002, broadens Lantheus' prostate cancer franchise. For POINT, the agreement pairs PNT2002 and PNT2003 with an ideal commercialization partner, and offsets launch and marketing risks, while still maintaining the value and independence of POINT's next generation radioligand platform. Lantheus expects the agreements to drive long-term, sustainable revenue and free cash flow growth and be accretive to its Adjusted Earnings Per Share (Adjusted EPS) shortly following commercialization of PNT2002.

Under the agreements, POINT will fund and complete its Phase 3 SPLASH trial for PNT2002, following which Lantheus will file the New Drug Application (NDA) in collaboration with POINT. For PNT2003, POINT will facilitate completion of the ongoing University Health Network (UHN)-sponsored ongoing OZM-067 study in Canada, while Lantheus will prepare and submit the regulatory filings in the U.S. Upon consummation of the agreements, the companies will form joint steering committees to oversee the clinical studies, regulatory filings, manufacturing and commercial readiness for both PNT2002 and PNT2003. POINT will develop commercial production capacity and manufacture clinical and commercial supply for both PNT2002 and PNT2003.

Lantheus has the rights to commercialize both assets post regulatory approval. The collaboration diversifies Lantheus' portfolio with two radiotherapeutic agents that could improve the way cancer is treated: PNT2002 is a PSMA-targeted 177Lu-based radiopharmaceutical therapy for metastatic castration-resistant prostate cancer (mCRPC) and combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope no-carrier-added 177Lu. Every year in the United States 70,000 men are eligible for treatment for mCRPC.

PNT2002 is currently in its Phase 3 study designed to evaluate superiority to the standard of care in mCRPC pre-chemotherapy patients who have failed one androgen receptor pathway inhibitor. PNT2003 is a somatostatin receptor (SSTR) targeted radioligand therapy with no-carrier-added 177Lu, in development for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). SSTRs are seen as ideal targets for NET therapy and somatostatin analogs (SSAs) have been developed with anti-secretory and anti-proliferative effects for NET therapy, and randomized clinical trials with somatostatin analogs have demonstrated efficacy.

PNT2003 is currently in a Phase 3 trial.


ę S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
LANTHEUS HOLDINGS, INC. 0.23% 60.8 Delayed Quote.19.31%
POINT BIOPHARMA GLOBAL INC. -1.98% 7.94 Delayed Quote.8.92%
All news about POINT BIOPHARMA GLOBAL INC.
02/02POINT Biopharma to Participate in Upcoming Investor Conferences
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialEnrollment for..
AQ
01/13POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
AQ
01/12POINT Biopharma Completes Enrollment in Phase 3 Trial of PNT2002 to Treat Prostate Canc..
MT
01/12POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
AQ
01/12Point Biopharma Completes Randomization in PNT2002’s Phase 3 Splash Trial
CI
01/12POINT Biopharma Global Inc. Completes Randomization in PNT2002’s Phase 3 SPLASH Tr..
CI
01/09Top Premarket Decliners
MT
2022Point Biopharma, Lantheus Close Licensing Deals for Cancer Treatment Candidates
MT
2022POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
AQ
More news
Analyst Recommendations on POINT BIOPHARMA GLOBAL INC.
More recommendations
Financials (USD)
Sales 2022 47,3 M - -
Net income 2022 -50,8 M - -
Net cash 2022 274 M - -
P/E ratio 2022 -14,0x
Yield 2022 -
Capitalization 839 M 839 M -
EV / Sales 2022 11,9x
EV / Sales 2023 7,62x
Nbr of Employees -
Free-Float 84,7%
Chart POINT BIOPHARMA GLOBAL INC.
Duration : Period :
POINT Biopharma Global Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POINT BIOPHARMA GLOBAL INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 7,94 $
Average target price 15,90 $
Spread / Average Target 100%
EPS Revisions
Managers and Directors
Joe McCann Chief Executive Officer & Director
William Demers Chief Financial Officer
Allan C. Silber Executive Chairman
Neil E. Fleshner Chief Medical Officer & Director
Jessica Jensen Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
POINT BIOPHARMA GLOBAL INC.8.92%839
REGENERON PHARMACEUTICALS, INC.4.12%83 640
VERTEX PHARMACEUTICALS5.19%77 269
WUXI APPTEC CO., LTD.15.80%40 679
BIONTECH SE-5.43%34 523
BEIGENE, LTD.16.80%26 752